Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of irinotecan and 3-AP in
treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy
such as irinotecan work in different ways to stop tumor cells from dividing so they stop
growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for
their growth and may help irinotecan kill more tumor cells by making them more sensitive to
the drug.